Cargando…

Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas

SIMPLE SUMMARY: Ovarian clear cell and mucinous carcinomas are less sensitive to chemotherapy. This can be explained by carcinogenic mechanisms and molecular biological features. Although chemotherapy with cytotoxic anticancer drugs has been evaluated by clinical studies, none have achieved better t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shoji, Tadahiro, Tatsuki, Shunsuke, Abe, Marina, Tomabechi, Hidetoshi, Takatori, Eriko, Kaido, Yoshitaka, Nagasawa, Takayuki, Kagabu, Masahiro, Baba, Tsukasa, Itamochi, Hiroaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656608/ https://www.ncbi.nlm.nih.gov/pubmed/34885229 http://dx.doi.org/10.3390/cancers13236120

Ejemplares similares

Comparison of Postoperative Adjuvant Chemotherapy and Concurrent Chemoradiotherapy for FIGO2018 Stage IIIC1 Cervical Cancer: A Retrospective Study
por: Kagabu, Masahiro, et al.
Publicado: (2021)

Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer
por: Shoji, Tadahiro, et al.
Publicado: (2021)

A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study)
por: Nagasawa, Takayuki, et al.
Publicado: (2023)

A New Therapeutic Strategy for Recurrent Ovarian Cancer―Bevacizumab beyond Progressive Disease
por: Shoji, Tadahiro, et al.
Publicado: (2019)

Immunotherapy for Uterine Cervical Cancer
por: Kagabu, Masahiro, et al.
Publicado: (2019)

Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions
por: Kagabu, Masahiro, et al.
Publicado: (2020)

A retrospective study of neoadjuvant chemotherapy plus radical hysterectomy versus radical hysterectomy alone in patients with stage II cervical squamous cell carcinoma presenting as a bulky mass
por: Takatori, Eriko, et al.
Publicado: (2016)

Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
por: Shoji, Tadahiro, et al.
Publicado: (2012)

A case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic review
por: Shoji, Tadahiro, et al.
Publicado: (2016)

Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass
por: Shoji, Tadahiro, et al.
Publicado: (2016)

A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report
por: Takatori, Eriko, et al.
Publicado: (2015)

Safe administration of bevacizumab combination chemotherapy for the patients with recurrent cervical cancer after pelvic radiotherapy: Two case reports
por: Shoji, Tadahiro, et al.
Publicado: (2018)

Analysis of the antitumor activity of gemcitabine and carboplatin against ovarian clear-cell carcinoma using the DNA damage marker γH2AX
por: Takatori, Eriko, et al.
Publicado: (2013)

Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report
por: Takatori, Eriko, et al.
Publicado: (2014)

Genome-wide analysis of microRNA to evaluate prognostic markers in isolated cancer glands and surrounding stroma in high-grade serous ovarian carcinoma
por: Sato, Chie, et al.
Publicado: (2020)

Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents
por: Takatori, Eriko, et al.
Publicado: (2012)

Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2]
por: Takeuchi, Satoshi, et al.
Publicado: (2020)

A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
por: Shoji, Tadahiro, et al.
Publicado: (2014)

Surgical management of non-invasive uterine clear cell carcinoma
por: Sugiyama, Toru, et al.
Publicado: (2017)

Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor
por: Kagabu, Masahiro, et al.
Publicado: (2023)

A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
por: Shoji, Tadahiro, et al.
Publicado: (2017)

Clinical Significance of Atypical Glandular Cells in the Bethesda System 2001: A Comparison with the Histopathological Diagnosis of Surgically Resected Specimens
por: Shoji, Tadahiro, et al.
Publicado: (2014)

Protein expression patterns in cancer-associated fibroblasts and cells undergoing the epithelial-mesenchymal transition in ovarian cancers
por: Fukagawa, Daisuke, et al.
Publicado: (2018)

An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
por: Shoji, Tadahiro, et al.
Publicado: (2018)

Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target
por: Tsang, Tsun Yee, et al.
Publicado: (2017)

Sensitivity to Anticancer Agents and Resistance Mechanisms in Clear Cell Carcinoma of the Ovary
por: Itamochi, Hiroaki, et al.
Publicado: (2002)

Clinical and reproductive outcomes of fertility-sparing surgery in stage I epithelial ovarian cancer
por: Watanabe, Takafumi, et al.
Publicado: (2020)

A case of primary ovarian signet-ring cell carcinoma treated with S-1/CDDP therapy
por: Shoji, Tadahiro, et al.
Publicado: (2020)

Mucin-poor and aggressive mucinous tubular and spindle cell carcinoma of the kidney: Two case reports
por: Uchida, Shiro, et al.
Publicado: (2017)

Efficacy and safety of standard of care with/without bevacizumab for platinum‐resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023
por: Shoji, Tadahiro, et al.
Publicado: (2021)

Mesenteric extraovarian Sertoli-Leydig cell tumor without DICER1 hotspot mutation: a case report
por: Osakabe, Mitsumasa, et al.
Publicado: (2019)

Rapid progression of recurrent disease in a patient with renal cell carcinoma with vaginal metastasis
por: Hisano, Mizuki, et al.
Publicado: (2020)

Mucinous carcinoma occurring in the male breast
por: ISHIDA, MITSUAKI, et al.
Publicado: (2014)

Primary Clear-Cell Sarcoma in the Mediastinum
por: Tanaka, Yumi, et al.
Publicado: (2014)

Mucinous cystic neoplasm of the pancreas activated during pregnancy
por: Kosumi, Keisuke, et al.
Publicado: (2015)

Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology
por: Kajiyama, Hiroaki, et al.
Publicado: (2014)

Refractory Hailey–Hailey disease cleared with upadacitinib
por: Murphy, Lauren, et al.
Publicado: (2023)

Profile of farletuzumab and its potential in the treatment of solid tumors
por: Sato, Seiya, et al.
Publicado: (2016)

The long-term survival in primary retroperitoneal mucinous cystadenocarcinoma: a case report
por: Tokai, Hirotaka, et al.
Publicado: (2017)

Primary mucinous carcinoma of the skin
por: Yamada, Takayuki
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ke24sa6c1bldbdn6erpc5hatt0